MASH & Obesity-Liver Axis
Obesity drives MASH progression with multiple new therapies entering clinical practice. The session covers resmetirom (Rezdiffra) real-world adoption and infrastructure requirements, GLP-1 effects on liver (ESSENCE semaglutide in MASH), multi-agonist trials (retatrutide, mazdutide) hepatic outcomes, FibroScan in obesity clinics for screening, MASH cirrhosis management, bariatric surgery effects on liver disease and MASH resolution, and primary-care screening pathways. Discussion addresses MASH-HCC surveillance, the comparison of MASH treatments mechanistically (THR-β vs incretin vs FGF21 vs PPAR), lanifibranor PPAR-pan-agonist, efruxifermin FGF21 analogue, equity in MASH care across populations, and the integration of hepatology, endocrinology and obesity medicine.
- Resmetirom (Rezdiffra) real-world
- ESSENCE semaglutide in MASH
- Multi-agonist hepatic outcomes
- FibroScan screening
- Bariatric surgery effects on liver
- Lanifibranor PPAR
- Efruxifermin FGF21
- MASH-HCC surveillance
Explore the full GSOD 2027 program
- 01GLP-1 & Incretin Therapies
- 02Bariatric Surgery
- 03Childhood & Adolescent Obesity
- 04Obesity Genetics & Epigenetics
- 05Metabolic Syndrome
- 06Behavioral & Lifestyle Interventions
- 07Gut Microbiome & Metabolism
- 08Health Equity in Obesity Care
- 09Policy, Environment & Prevention
- 10Weight Loss Maintenance
- 11Eating Disorders & Obesity
- 12Sarcopenic Obesity
- 13Hormonal Drivers
- 14Cardiometabolic Complications
- 16Sleep & Obesity
- 17Workplace & School Programs
- 18Pharmacotherapy Pipeline
- 19Type 1 Diabetes
- 20Type 2 Diabetes
- 21Diabetic Retinopathy
- 22Diabetic Neuropathy
- 23Diabetic Kidney Disease
- 24Polycystic Ovary Syndrome
- 25Thyroid & Weight
- 26Insulin Resistance
- 27Lipid Metabolism
- 28Body Composition
- 29Body Image & Mental Health
- 30Diabetes in Pregnancy
- 31Telemedicine in Obesity
- 32Endocrine Disruptors
- 33Health Coaching
- 34Geriatric Obesity
- 35Stigma & Communication